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PGI9
COST-UTILITY-ANALYSIS OF PEGINTERFERON ALFA-2B PLUS
RIBAVIRIN VERSUS INTERFERON ALFA-2B PLUS RIBAVIRIN AS
INITIAL THERAPY FOR CHINESE NAIVE PATIENTS WITH
CHRONIC HEPATITIS C
Tarn YH1, Lin WA2
1Taipei City Hospital,Taipei,Taiwan, 2National Defence Medical Center,
Taipei,Taiwan
OBJECTIVE: Aims: To estimate the cost effectiveness of treat-
ment with peginterferon alfa-2b plus ribavirin compared with
interferon alfa-2b plus ribavirin for initial treatment of patients
with chronic hepatitis C. METHODS: Individual patient level
data from a randomised clinical trial with peginterferon plus rib-
avirin were applied to a Markov model to project lifelong clini-
cal outcomes. Economic estimates and quality of life were based
on Taiwan patient data and published data. We used a societal
perspective and applied a 3% annual discount rate. RESULTS:
Compared with no antiviral therapy, interferon alfa-2b plus
weight based dosing of ribavirin or peginterferon alfa-2b plus
weight based dosing of ribavirin 24 weeks therapy increased
quality adjusted life year (QALY) on overall hepatitis C patients
by 6.5 and 6.7 years, respectively. And the life long treatment
costs are lower than no antiviral therapy. The peginterferon plus
weight based dosing of ribavirin therapy on genotype I patients
is dominate. On the other hand, use interferon plus weight based
dosing of ribavirin to treat non-genotype I Chinese patients is
the most cost-effectiveness therapy. If the SVR of interferon plus
weight based dosing of ribavirin is below 67.8%, the best strat-
egy of treating non-genotype I Chinese patients will be The
peginterferon plus weight based dosing of ribavirin. CONCLU-
SIONS: Peginterferon alfa-2b plus ribavirin should reduce the
incidence of liver complications, prolong life, improve quality of
life, and be cost effective for the initial treatment of Chinese
chronic hepatitis C.
PGI10
COST OF ILLNESS IN US EMPLOYEES WITH AND WITHOUT
GASTROESOPHAGEAL REFLUX DISEASE
Brook R1, Campbell S2, Wahlqvist P3,Wallander MA4,
Kleinman N2,Wiklund I4, Smeeding J5
1The JeSTARx Group, Newfoundland, NJ, USA, 2The HCMS Group,
Cheyenne, WY, USA, 3AstraZeneca R&D, Mölndal, AL, Sweden,
4AstraZeneca R&D, Mölndal, Sweden, 5The JeSTARx Group, Dallas,
TX, USA
OBJECTIVE: To assess the Annual Cost of Illness (CoI) of
GERD in an employed population. METHODS: A retrospective
analysis was conducted using the Human Capital Management
Services Research Reference database of multiple large geo-
graphically diverse US based employees with data from 2001
through 2004. Data included medical, pharmacy, payroll and
demographic data. The analysis compared the direct medical
costs by Place of Service (PoS: doctor’s ofﬁce, inpatient hospital,
outpatient hospital or clinic, emergency department, laboratory,
other) for a subset of employees where this data was available.
ICD-9 Codes were used to distinguish employees with GERD
from the non-GERD cohort. The index date in the GERD cohort
was deﬁned as the date of ﬁrst diagnosis during 2001 or later,
while the average GERD index date was used in the non-GERD
cohort. Regression modelling was used to measure the cost dif-
ferences between employees with GERD and employees without
GERD while controlling for age, job tenure, gender, salary,
region, and comorbidities. RESULTS: Data were available 
for 267,269 employees (4.3% with GERD). The mean age of
employees with GERD was 43 years, and 94% were full time
employees. All of the annual CoI and PoS comparisons were sta-
tistically different (all P < 0.001). GERD was associated with an
annual mean incremental cost of $3,355, of which direct medical
costs accounted for 65%, prescription drug costs for 17%, and
indirect costs in terms of sick leave, short- and long-term dis-
ability, and workers’ compensation for 19%. The largest PoS
component (47%) was in the category “outpatient hospital or
clinic”. CONCLUSIONS: GERD is associated with substantial
direct and indirect costs, of which direct medical costs exclud-
ing prescription medications contributed to 65% of total incre-
mental costs in this study.
PGI11
ECONOMIC BURDEN OF ENDOSCOPY-RELATED
INFECTIONS, PSEUDO-INFECTIONS AND TOXIC REACTIONS
Seoane-Vazquez E1, Rodriguez Monguio R1,Visaria J1, Carlson A2
1Ohio State University, Columbus, OH, USA, 2Data Intelligence
Consultants, LLC, Eden Prairie, MN, USA
OBJECTIVES: The objective of this study is to analyze the eco-
nomic burden of exogenous endoscopy-related infections,
pseudo-infections and toxic reactions in the U.S. in 2004.
METHODS: The economic burden was estimated from the U.S.
health care perspective. The number of events and patients
involved was estimated based on a review of the literature. An
analysis of the causes of contamination was conducted to eval-
uate preventable events. The use of resources was estimated for
patients exposed, contaminated and experiencing clinical symp-
toms. The use of resources included chart reviews, physician
visits, clinical tests, and interventions required for the treatment
of the infections and toxic reactions. The valuation of resources
was based on a review of the literature. A sensitivity analysis of
the incidence of endoscopy-related events and the use and valu-
ation of resources was conducted. RESULTS: The analysis
yielded a baseline incidence of 2741 patients exposed to
endoscopy-related events; 208 patients contaminated; and 113
patients experiencing clinical symptoms. It was estimated that
91.7% of the cases could be prevented if better infection control
practices were implemented, and that 93.3% of the cases could
be prevented if protective endoscope sheaths were used during
procedures. The total direct medical cost associated with
endoscopy-related infections occurring in the US in 2004 was
estimated at $7.6 million (range = $2.8–$14.7 million). Health
care expenditures for patients experiencing clinical symptoms
and evaluation of patient exposed represented 61.3% and 34.8%
of the total cost respectively. CONCLUSIONS: The analysis of
the economic burden associated with endoscopy-related events
reveals the signiﬁcance of the costs related to the care of patients
experiencing clinical symptoms, and the review of patients’
medical charts and the clinical evaluation of exposed patients.
The use of protective endoscope sheaths during procedures,
improved infection control, and surveillance systems could
reduce the economic burden associated with endoscopy-related
events.
PGI12
COST-UTILITY ANALYSIS OF TEGASEROD FOR THE
TREATMENT OF IRRITABLE BOWEL SYNDROME
Chen SY, Lin PJ, Biddle AK
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
OBJECTIVES: Tegaserod appears to be safe and effective for
treating constipation-predominant irritable bowel syndrome
(IBS-C). The present study evaluates whether tegaserod is cost-
effective compared to usual care, which consists of education,
reassurance, suggestions on lifestyle and diet, and discussion
about psychosocial issues. METHODS: The study employed a
Markov-cycle tree to evaluate the medical and economic out-
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comes of repeated treatment with tegaserod compared to usual
care in a hypothetical cohort of 1000 female patients ages 18–65
years. Probability and utility estimates were obtained from clin-
ical trials; costs were derived from published fee schedules and
other sources. Using a societal perspective over a 60-week time
horizon, treatment of tegaserod was compared to usual care
based on costs, quality-adjusted life-years (QALYs), and incre-
mental cost-utility ratio (ICUR). One-way sensitivity analyses
were conducted to assess the effect of varying baseline estimates
within plausible ranges on ICUR, and a probabilistic sensitivity
analysis in which parameters were varied simultaneously over
predeﬁned probability distributions was conducted. RESULTS:
Although the cost of tegaserod treatment was higher than 
that of usual care ($1,070,761 vs. $173,000), the outcomes of
tegaserod treatment were also better than those of usual care
(834 QALYs vs. 806 QALYs). The resulting incremental cost-
utility ratio was $32,113/QALY. The probability that tegaserod
remains cost-effective within the generally accepted $50,000 per
QALY decision threshold is more than 80%. One-way sensitiv-
ity analyses demonstrate that the results are most sensitive to the
costs of tegaserod and the utilities associated with treated and
untreated IBS. In probabilistic sensitivity analyses, the costs of
tegaserod accounted for 77% of variation in the ICUR. CON-
CLUSIONS: For treatment of IBS-C in females, tegaserod is cost-
effective compared to usual care.
PGI13
A COST UTILITY ANALYSIS OF PEGUINTERFERON ALFA 2B
(12KD) (PEG2B) VERSUS PEGUINTERFERON ALFA 2A (40KD)
(PEG2A) FOR THE TREATMENT OF CHRONIC HEPATITIS C
(CHC) IN BRAZIL
Fonseca M,Araujo G
Axia.Bio Consulting, São Paulo, Brazil
OBJECTIVES: The Brazilian government has published guid-
ance for the use of peguilated interferons for the treatment of
CHC in adults. However, there is no differentiation between the
drugs either concerning efﬁcacy or cost effectiveness. We used a
previously published Brazilian Markov model to compare these
two drugs in terms of cost utility. METHODS: The Brazilian
Markov model describes the clinical history of CHC in which
cohorts of hepatitis C virus (HCV) patients receive peginterferon
alfa 2b or peginterferon alfa 2a for either 48 or 24 weeks accord-
ing to genotype and liver histology and were followed for their
life expected life time. The reference patient was a 30-year-old
male with CHC without cirrhosis. The SVRs to PEG2b and
PEG2a were 48% and 46% for HCV genotype 1 and 88% and
76% for non-1, respectively. Quality of life for each health state
was based on literature. Costs for each health state was based
on three Delphi panels, one with hepatologists, one with inten-
sivists and another with oncologists. Costs in 2005 reais and ben-
eﬁts were discounted at 3%. RESULTS: In HCV genotype 1
PEG2b increases life expectancy (LY) by 0.07 years and quality
adjusted life expectancy (QALY) by 0.13 years compared to
PEG2a. In these patients PEG2b is less costly than PEG2a 
(R$3.763,33 difference). In HCV non-genotype 1 patients
PEG2b increases LY by 0.44 and QALY by 0.76. Also, in HCV
non-genotype 1 patients PEG2b was less costly than PEG2a 
(R$6.371,04 difference). CONCLUSIONS: Peguinterferon alfa
2b is dominant, in pharmacoeconomics terms, in comparison to
PEG2a for the treatment of HCV adult patients, in Brazil.
PGI14
COST-UTILITY OF A MODALITY OF “C” VIRUS HEPATITIS
TREATMENT IN PATIENTS THAT DO NOT RESPOND TO
INTERFERON PLUS RIBAVIRIN IN MEXICO
Nevarez-Sida A, Constantino-Casas P, Garcia-Contreras F
Mexican Institute of Social Security, México, Distrito Federal, Mexico
OBJECTIVE: To determine cost-utility of the treatment alterna-
tives of C virus hepatitis (CVH) in the Mexican Institute of Social
Security (IMSS): a) Peginterferon, b) Peginterferon plus Rib-
avirin, c) Peginterferon plus Ribavirin plus Thymosin in those
patients that did not respond to interferon plus Ribavirin, and
d) and ﬁnally, not using any drug. METHODS: A cost-utility
analysis was performed using a decision tree and a Markov
model to simulate a cohort of 30-year-old male patients with
CVH without chronic complications. The follow-up was till their
death. The cost information was gotten from a Mexican expert
panel and effectiveness data were taken from a clinical trial in
Mexican population. The perspective used was institutional and
a 3% discount rate was applied for costs and effectiveness. Costs
were reported in 2005 US dollars. The sensitivity analysis per-
formed included one-way, two-way, threshold and probabilistic.
Acceptability curves and health net beneﬁts were estimated.
RESULTS: The most costly and least effective option was not
using any drug, with $4716 per QALY. The alternative with less
cost per QALY was the one that included Thymosin ($2246) fol-
lowed by Peginterferon plus Ribavirin ($2492) and Peginterferon
alone ($3229). CONCLUSIONS: The alternatives of not using
any drug and the one based on Peginterferon were dominated.
Triple therapy (Peginterferon plus Ribavirin plus Thymosin) was
the most expensive and effective. Therefore the decision about
using triple therapy and Peginterferon plus Ribavirin will depend
on willingness to pay.
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PRIOR AUTHORIZATION AND THE APPROPRIATE
PRESCRIBING OF TEGASEROD: A LOOK AT A MANAGED
CARE POPULATION
Margolis J1,Tan J1,Wertz D1, Cerulli A2, Kahler K2
1Healthcore, Inc, Wilmington, DE, USA, 2Novartis Pharmaceuticals
Corporation, East Hanover, NJ, USA
OBJECTIVE: To assess the effect of prior authorization (PA) on
the appropriate gastrointestinal (GI) prescribing of tegaserod in
a managed care population. METHODS: Retrospective analysis
was conducted of pharmacy and medical claims data of
tegaserod users from four geographically diverse managed care
health plans. Members who were continuously enrolled and ini-
tiated on tegaserod therapy between August 1, 2002 and Decem-
ber 31, 2003 were included in the study. The ﬁrst prescription
ﬁll date for tegaserod during this period was considered the index
prescription date. Index diagnosis visit was deﬁned as the closest
physician visit with a GI-related diagnosis either before or after
the index prescription date. Diagnostic characteristics were 
evaluated during a 2-year period (1 year before and 1 year after
the index prescription date). Appropriate GI prescribing of
tegaserod, deﬁned as a claim for IBS or at least one of its symp-
toms—abdominal pain, bloating, or constipation—was assessed
for plans with and without PA. RESULTS: In total, 2638
tegaserod users had an index diagnosis visit for a GI-related dis-
order; 93.5% were female, and the mean age was 48.6 (SD =
13.7) years. During the 24-month observation period, 93.6% of
the patients were appropriately prescribed tegaserod. Speciﬁcally,
they were diagnosed with IBS (56.4%), constipation (21.2%),
abdominal pain (15.8%), or bloating (1.3%). There were no dif-
